Zhejiang Anglikang Pharmaceutical Co Ltd Class A - Asset Resilience Ratio

Latest as of March 2026: 9.11%

Zhejiang Anglikang Pharmaceutical Co Ltd Class A (002940) has an Asset Resilience Ratio of 9.11% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check 002940 strategic asset allocation to assess the company's strategic physical and investment asset allocation.

Liquid Assets

CN¥283.96 Million
≈ $41.55 Million USD Cash + Short-term Investments

Total Assets

CN¥3.12 Billion
≈ $455.88 Million USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio Trend (2018–2025)

This chart shows how Zhejiang Anglikang Pharmaceutical Co Ltd Class A's Asset Resilience Ratio has changed over time. See Zhejiang Anglikang Pharmaceutical Co Ltd (002940) net asset quality to measure how much of total assets are equity-financed.

Liquid Assets Composition Over Time

This chart breaks down Zhejiang Anglikang Pharmaceutical Co Ltd Class A's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 002940 stock market capitalisation.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents CN¥0.00 0%
Short-term Investments CN¥283.96 Million 9.11%
Total Liquid Assets CN¥283.96 Million 9.11%

Asset Resilience Insights

  • Limited Liquidity: Zhejiang Anglikang Pharmaceutical Co Ltd Class A maintains only 9.11% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

Zhejiang Anglikang Pharmaceutical Co Ltd Class A Industry Peers by Asset Resilience Ratio

Compare Zhejiang Anglikang Pharmaceutical Co Ltd Class A's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603
Drug Manufacturers - Specialty & Generic 11.60%
SIMCERE PHARMAC. GRP LTD
F:S2P
Drug Manufacturers - Specialty & Generic 0.44%
Curaleaf Holdings Inc.
TO:CURA
Drug Manufacturers - Specialty & Generic 3.73%
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755
Drug Manufacturers - Specialty & Generic 24.59%
Walvax BioTech
SHE:300142
Drug Manufacturers - Specialty & Generic 2.20%
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091
Drug Manufacturers - Specialty & Generic 26.36%
Cronos Group Inc
TO:CRON
Drug Manufacturers - Specialty & Generic 69.94%
Renhe Pharmacy Co Ltd
SHE:000650
Drug Manufacturers - Specialty & Generic 37.54%

Annual Asset Resilience Ratio for Zhejiang Anglikang Pharmaceutical Co Ltd Class A (2018–2025)

The table below shows the annual Asset Resilience Ratio data for Zhejiang Anglikang Pharmaceutical Co Ltd Class A.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-12-31 3.47% CN¥102.26 Million
≈ $14.96 Million
CN¥2.95 Billion
≈ $431.80 Million
+2.25pp
2024-12-31 1.21% CN¥36.04 Million
≈ $5.27 Million
CN¥2.97 Billion
≈ $435.27 Million
+0.88pp
2023-12-31 0.33% CN¥10.00 Million
≈ $1.46 Million
CN¥3.02 Billion
≈ $441.92 Million
-2.34pp
2022-12-31 2.67% CN¥69.30 Million
≈ $10.14 Million
CN¥2.60 Billion
≈ $379.89 Million
-0.19pp
2021-12-31 2.86% CN¥59.60 Million
≈ $8.72 Million
CN¥2.08 Billion
≈ $304.89 Million
+2.94pp
2020-12-31 -0.08% CN¥-1.53 Million
≈ $-224.55K
CN¥1.94 Billion
≈ $283.99 Million
-7.30pp
2019-12-31 7.22% CN¥100.05 Million
≈ $14.64 Million
CN¥1.38 Billion
≈ $202.67 Million
+3.48pp
2018-12-31 3.75% CN¥55.08 Million
≈ $8.06 Million
CN¥1.47 Billion
≈ $215.14 Million
--
pp = percentage points

About Zhejiang Anglikang Pharmaceutical Co Ltd Class A

SHE:002940 China Drug Manufacturers - Specialty & Generic
Market Cap
$841.89 Million
CN¥5.75 Billion CNY
Market Cap Rank
#9834 Global
#2616 in China
Share Price
CN¥28.52
Change (1 day)
+2.19%
52-Week Range
CN¥27.38 - CN¥64.70
All Time High
CN¥249286.54
About

Zhejiang AngLiKang Pharmaceutical CO.,LTD., a pharmaceutical company, engages in manufacturing APIs and pharmaceutical preparations for oral cephalosporins, cardiovascular, and kidney diseases. The company also offers products in the areas of anti-infection, cardiovascular, urinary system (nephropathy), anesthesia and pain, and anti-androgen. The company was founded in 2001 and is based in Shengz… Read more